Needham Maintains Buy on Autolus Therapeutics, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Autolus Therapeutics (NASDAQ:AUTL) and raises the price target from $8 to $9.

February 12, 2024 | 11:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum maintains a Buy rating on Autolus Therapeutics and raises the price target from $8 to $9.
The increase in price target by a reputable analyst like Gil Blum from Needham suggests a positive outlook on Autolus Therapeutics' stock. This endorsement is likely to instill confidence in investors, potentially driving up the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100